ICER releases draft evidence report on treatments for amyotrophic lateral sclerosis

ICER

14 June 2022 - Public comment period now open until 13 July 2022; requests to make oral comment during public meeting also being accepted.

The ICER today released a draft evidence report assessing the comparative clinical effectiveness and value of AMX0035 (Amylyx Pharmaceuticals) and oral edaravone (Mitsubishi Tanabe) for the treatment of amyotrophic lateral sclerosis.

Read ICER Announcement

Michael Wonder

Posted by:

Michael Wonder